JP Morgan Maintains Overweight on EyePoint Pharmaceuticals, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Tessa Romero maintains an Overweight rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) but lowers the price target from $35 to $32.
June 04, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Tessa Romero maintains an Overweight rating on EyePoint Pharmaceuticals but lowers the price target from $35 to $32.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100